The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -766,409 | - |
| Loss on disposal of fixed assets | -32 | - |
| Amortization of intangible assets | 801 | - |
| Stock-based compensation expense | 84,693 | - |
| Depreciation and amortization | 5,513 | - |
| Change in fair value of warrant liabilities and contingent earn-out shares | 2,731 | - |
| Non-cash interest expense on liability related to sale of future royalties | 12,294 | - |
| Net amortization of premium or discount on marketable securities | 23,277 | - |
| Amortization of operating lease right-of-use asset | 5,542 | - |
| Impairment of assets | 0 | - |
| Accounts receivable | 0 | - |
| Prepaid expenses and other current assets | 6,290 | - |
| Accounts payable | 20,036 | - |
| Accrued expenses and other current liabilities | 57,663 | - |
| Operating lease liability | -1,198 | - |
| Long-term deposits | 4,723 | - |
| Other noncurrent assets | 12,718 | - |
| Other noncurrent liabilities | 1,807 | - |
| Net cash used in operating activities | -623,503 | - |
| Purchases of marketable securities | 1,498,365 | - |
| Maturities of marketable securities | 1,549,222 | - |
| Sales of marketable securities | 6,384 | - |
| Purchases of property and equipment | 14,065 | - |
| Net cash provided by (used in) investing activities | 43,176 | - |
| Proceeds from issuance of common stock upon at-the-market offering, net of issuance costs | 0 | - |
| Proceeds from issuance of common stock under equity incentive plans | 6,973 | - |
| Proceeds from issuance of common stock related to employee stock purchase plan | 4,644 | - |
| Proceeds from the sale of future royalties | 244,215 | - |
| Exercise of warrants | 4 | - |
| Deferred offering costs | -29 | - |
| Net cash provided by financing activities | 255,865 | - |
| Restricted cash | - | 3,916 |
| Net decrease in cash, cash equivalents and restricted cash | -324,462 | - |
| Cash and cash equivalent | - | 402,438 |
| Cash and cash equivalents at beginning of period | 546,762 | - |
| Cash, cash equivalents and restricted cash - end of period | - | 406,354 |
| Cash and cash equivalents at end of period | 222,300 | - |
Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. (RVMD)